Brain volume loss linked to new Alzheimer’s immunotherapies, such as lecanemab, is caused by the removal of amyloid plaques rather than neuronal damage.
In mice, inhibiting protein S-palmitoylation Counteracted accumulation of harmful proteins in neurons and delayed onset and progression of cognitive decline.